Exogenous insulin use and hypertension in adult patients with type 2 diabetes mellitus

Archives of Internal Medicine

Volumn 166, Issue 11, 2006, Pages 1184-1189

  Tseng, Chin Hsiao ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG USE; FEMALE; HEALTH INSURANCE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; TAIWAN;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; INSULIN; MALE; MIDDLE AGED;

EID: 33745031775     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.11.1184     Document Type: Article

References (31)

1. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension: the San Antonio Heart Study. Arch Intern Med. 1996;156:1994-2001.
2. Goff DC Jr, Zaccaro DJ, Haffner SM, Saad MF; Insulin Resistance Atherosclerosis Study. Insulin sensitivity and the risk of incident hypertension: insights from the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2003;26:805-809.
3. Modan M, Almog S, Fuchs Z, Chetrit A, Lusky A, Halkin H. Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension. 1991;17:565-573.
4. Rewers M, Zaccaro D, D'Agostino R, et al; Insulin Resistance Atherosclerosis Study Investigators. Insulin sensitivity, insulinemia, and coronary artery disease: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27:781-787.
5. Lakka HM, Lakka TA, Tuomilehto J, Sivenius J, Salonen JT. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med. 2000;160:1160-1168.
6. Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs highdensity lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002;162:2597-2604.
7. Pyorala M, Miettinen H, Laakso M, Pyorala K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care. 2000;23:1097-1102.
8. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation. 1998;97:996-1001.
9. Liu QZ, Knowler WC, Nelson RG, et al. Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians: cross-sectional and prospective analyses. Diabetes. 1992;41:1141-1150.
10. Janka HU, Ziegler AG, Standl E, Mehnert H. Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabete Metab. 1987;13:359-364.
11. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care. 2001;24:1614-1619.
12. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med. 2000;133:81-91.
13. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes, VIII: evaluation of insulin therapy: final report. Diabetes. 1982;31(suppl 5):1-81.
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
15. Baron AD. Hemodynamic actions of insulin. Am J Physiol. 1994;267:E187-E202.
16. Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S. Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab. 2003;285:E123-E129.
17. Kern W, Peters A, Born J, Fehm HL, Schultes B. Changes in blood pressure and plasma catecholamine levels during prolonged hyperinsulinemia. Metabolism. 2005;54:391-396.
18. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105:576-582.
19. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care. 1990;13:631-654.
20. Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care. 2004;27:1605-1609.
21. Tseng CH, Chong CK, Sheu JJ, Wu TH, Tseng CP. Prevalence and risk factors for stroke in type 2 diabetic patients in Taiwan: a cross-sectional survey of a national sample by telephone interview. Diabet Med. 2005;22:477-482.
22. World Health Organization. The Asia-Pacific perspective: redefining obesity and its treatment. Available at: http://www.iotf.org. Accessed September 20, 2005.
23. Stout RW. Development of vascular lesions in insulin-treated animals fed a normal diet. BMJ. 1970;3:685-687.
24. Duff GL, Brechin DJ, Finkelstein WE. The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit, IV: the effect of insulin therapy on the inhibition of atherosclerosis in the alloxan-diabetic rabbit. J Exp Med. 1954;100:371-380.
25. Nordestgaard BG, Agerholm-Larsen B, Stender S. Effect of exogenous hyperinsulinaemia on atherogenesis in cholesterol-fed rabbits. Diabetologia. 1997;40:512-520.
26. Nosadini R, Sambataro M, Thomaseth K, et al. Role of hyperglycemia and insulin resistance in determining sodium retention in non-insulin-dependent diabetes. Kidney Int. 1993;44:139-146.
27. Ling BN, Matsunaga H, Ma H, Eaton DC. Role of growth factors in mesangial cell ion channel regulation. Kidney Int. 1995;48:1158-1166.
28. Rahmouni K, Morgan DA, Morgan GM, et al. Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. J Clin Invest. 2004;114:652-658.
29. Delbosc S, Paizanis E, Magous R, et al. Involvement of oxidative stress and NADPH oxidase activation in the development of cardiovascular complications in a model of insulin resistance, the fructose-fed rat. Atherosclerosis. 2005;179:43-49.
30. Muis MJ, Bots ML, Bilo HJ, et al. High cumulative insulin exposure: a risk factor of atherosclerosis in type 1 diabetes? Atherosclerosis. 2005;181:185-192.
31. Council for Economic Planning and Development. Taiwan Statistical Data Book. http://www.cepd.gov.tw/upload/OVERALL/PubStat/DataBook/ databook2004@212851.05638829482@.pdf. Accessed September 20, 2005.